Age-related macular degeneration (AMD) is the most common cause of legal blindness among people over 50 years of age in the developed world. In spite of significant basic and clinical research, its pathogenesis remains poorly understood. Aging, smoking, and oxidative stress are some of the wellcharacterized risk factors for AMD.
is no effective treatment for the more prevalent non-exudative AMD other than antioxidant supplements (vitamin C, vitamin E, beta-carotene, and zinc), which are effective in a 25% reduction of the risk of progression for patients with intermediate and advanced AMD. 12 Non-exudative AMD is triggered by abnormalities in the RPE, a monolayer of cells that lies beneath the photoreceptor cells and normally provides critical metabolic support to these light-sensing cells. 2 Histolopathological studies have suggested that loss of RPE is an early and pivotal event in the development of AMD. The dysfunction and loss of RPE result in photoreceptor degeneration, leading to the irreversible loss of vision. The molecular mechanism for RPE dysfunction likely involves multiple factors including genetic predisposition, oxidative stress, formation of drusen, accumulation of lipofuscin, and local inflammation. 2 Death of RPE in AMD demonstrates characteristic features of apoptosis, a highly regulated cell death program. 13, 14 In cultured RPE cells, apoptosis can be induced by different death stimuli including light exposure, oxidants, and activated cytotoxic T lymphocytes.
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Soluble Fas Ligand
FasL is a 40kDa type II transmebrane protein of the tumor necrosis factor (TNF) family. 6 
Fas Ligand/Fas in the Retinal Pigment Epithelium
In the normal eye, FasL is weakly expressed in the RPE monolayer. 13 However, increased FasL expression has been found in the residual RPE monolayer of the 24 In another early study using the excised neovascular membrane from AMD patients, an association between Fas expression, but not FasL expression, and the extent of apoptosis of RPE is found. 13 Little attention has been given to the fact that RPE cells also express Fas. Our study using cultured human RPE has shown that the level of cell-surface Fas is much higher than that of FasL in RPE. 20 Under normal culture conditions, these expression levels are insufficient to activate apoptosis on single or neighboring RPE cells.
However, when oligomerization of Fas is facilitated with a high concentration of recombinant sFasL and agonist anti-Fas antibody, apoptosis can be induced. to Fas-mediated apoptosis. This may act as an important mechanism of RPE loss that is the earliest finding in both non-exudative and exudative AMD.
Soluble Fas Ligand and Age-related Macular Degeneration
Altered cytokine production, along with lymphopenia and abnormal immune response, is frequently observed in aging and age-related diseases. Oxidative stress, infection, and inflammation can upregulate FasL expression and stimulate sFasL release from T cells, monocytes, macrophages, endothelial cells, and other cell types. 27, 28 Our laboratory has previously shown that redox states of human plasma pools become oxidized in association with increased age. 29 In an ancillary study to the Age-Related Eye Disease Study (AREDS), we found that the AREDS antioxidant supplements prevent oxidation of cystine/cysteine redox in AMD patients. 30 Therefore, we hypothesized that oxidative stress, in addition to its local effect in the eye-i.e. upregulating FasL and Fas expression in RPE and triggering autocrine and paracrine death in RPE cells-may also exhibit its systemic effect by elevating FasL expression in circulating blood cells such as T cells and macrophages or endothelial cells in blood vessels and stimulating release of sFasL from these cells into the blood circulation. When blood with high plasma sFasL circulates to the retina, sFasL may reach the subretinal space and bind to the Fas receptor on RPE and cause cell death. To test this hypothesis, we measured plasma sFasL concentrations in 230 subjects with ages ranging from 45 to 85 years, including 69 patients with AMD. 11 In non-AMD subjects, the levels of plasma sFasL ranged from 0 to 1.63ng/ml. In AMD patients, sFasL ranged from 0 to 2.43ng/ml. When the plasma sFasL levels were examined as a function of age, a significant correlation was identified between the sFasL and age in the non-AMD subjects (see Figure 1 ).
In addition, gender appeared as an important factor. The sFasL levels in non-AMD females were lower than those in non-AMD males. However, the linear regression lines had very similar slopes (p=0.94), indicating that the effect of age on sFasL is similar for both sexes. The AMD subjects tended to have significantly higher sFasL levels than the non-AMD group (see Figure 2) . It has been shown that serum antibodies for Chlamydia pneumoniae proteins are associated with increased risk for AMD development and progression. 4 At lower concentrations or in the absence of accessory molecules, sFasL exerts its pro-inflammatory effects. 7 A correlation between serum sFasL and CRP is observed in inflammatory diseases. 34, 35 Therefore, in addition to its function in RPE apoptosis, plasma sFasL may be a potential peripheral biochemical marker of AMD risk. However, results from such cross-sectional studies of peripheral biomarker measurements do not discern initiating and late events and sometimes are influenced by other pre-existing disease conditions. Large-scale prospective studies involving carefully phenotyped cohorts of subjects will be required to confirm these initial findings, clearly establish the utility of sFasL as a biomarker of AMD risk, and determine whether activation of the Fas system represents as a key mechanism of AMD.
Summary
The combination of the findings, i.e. that sFasL is increased in plasma with age, that increased plasma concentration of sFasL is associated with AMD, that RPE cells are preferentially lost during AMD, and that RPE cells are sensitive to sFasL, suggest that Fas-mediated apoptosis could be an important mechanism contributing to the development and progression of AMD (see Figure 3) . 
